Introduction of Respiratory Devices Industry
Respiratory devices are medical equipment used to assist patients in breathing or improving pulmonary function. These include ventilators, oxygen concentrators, nebulizers, CPAP machines, and spirometers, which are crucial for managing chronic respiratory conditions like COPD, asthma, and sleep apnea across hospital, homecare, and emergency settings.
Industry Dynamics of Respiratory Devices
The global respiratory devices market is driven by rising incidences of chronic respiratory diseases, aging populations, technological advancements, and increasing demand for home-based care, while facing regulatory challenges and cost containment pressures. For instance, in 2023, the BRFSS survey reported that 9.9% of U.S. adults and 6.9% of children across 27 states had current asthma, while 6.2% of adults had been diagnosed with COPD. Additionally, 14% of adults, accounting for about 34.7 million people reported having chronic lung disease. However, high device costs and regulatory challenges is anticipated to hinder market expansion.
Competitive Landscape of Respiratory Devices Industry
Leading Players of Respiratory Devices Market
The leading companies in the global medical device market maintain their dominant positions due to a strategic blend of technological innovation, global reach, diversified product portfolios, and acquisitions. Key players include:
- Koninklijke Philips N.V.
- Medtronic
- ResMed Inc.
- Fisher & Paykel Healthcare Corporation Limited
- Drägerwerk AG & Co. KGaA
- Masimo Corporation
- Getinge AB
- GE HealthCare
- AdaptHealth Corp.
Koninklijke Philips N.V., Medtronic, and ResMed Inc. lead the global respiratory devices market due to their strong innovation pipelines, global reach, and comprehensive product portfolios. Philips offers advanced ventilators and oxygen concentrators, catering to both hospital and homecare settings. Medtronic dominates with critical care ventilators and invasive/non-invasive solutions.ResMed Inc. is a global leader in sleep apnea devices, especially CPAP machines, and leverages digital health platforms to improve patient adherence and remote monitoring. Other prominent players such as Fisher & Paykel Healthcare, Drägerwerk, and Masimo bring depth through specialized offerings like humidification systems, respiratory monitoring, and patient safety solutions. Their collective R&D, regulatory compliance, and global logistics capabilities solidify their standing in this fast-evolving market.
Upcoming Players of Respiratory Devices Market
There are several emerging players in the Respiratory devices market that are gaining traction due to their focus on next-generation technologies, novel therapeutic approaches, and addressing unmet clinical needs. Key upcoming players are:
- X-COR Therapeutics
- Circadia Health
- Aerin Medical
- Hospitech Respiration
Emerging players like X-COR Therapeutics and Circadia Health are gaining traction by addressing critical unmet needs with breakthrough innovation. Meanwhile, Aerin Medical offers non-invasive treatments for nasal airway obstruction that enhance breathing without surgery, indirectly supporting respiratory wellness. Additionally, Hospitech Respiration is innovating airway management through its AnapnoGuard system, which prevents ventilator-associated complications, making it valuable in critical care units.The Respiratory Medical Devices Market is generally considered to be moderately concentrated, with a mix of large global players and numerous regional and niche companies. Top 5–6 companies control 50–65% of the market, especially in hospital-grade ventilators and sleep apnea devices. This is due to the specialized nature of these devices, requiring high technical expertise and substantial financial investment for development.
Technological Developments in Respiratory Devices Industry
3D Printing in Device Manufacturing
3D printing is revolutionizing respiratory device manufacturing by enabling rapid prototyping, customization, and cost-effective production. It’s especially useful for patient-specific masks, ventilator components, and airway stents. In March 2025, Michigan Medicine and Materialise launched a clinical trial to study 3D-printed bioresorbable implants for children with tracheobronchomalacia, a rare and life-threatening airway condition. The research marks a first-of-its-kind effort in pediatric respiratory care innovation.
Nanotechnology in Respiratory Treatments
Nanotechnology enhances drug delivery in respiratory care by improving absorption and targeting, especially in asthma and COPD therapies. Pulmatrix is pioneering inhalable dry-powder formulations using iSPERSE nanotech to deliver drugs deeper into the lungs.Nanocarriers also reduce side effects by localizing treatment, and nanofiber filters are being integrated into respiratory masks and devices to improve pathogen filtration and air quality.
Biosensors and Wearable Respiratory Monitors
Biosensors embedded in wearables are transforming respiratory monitoring by enabling real-time, non-invasive tracking of parameters like respiratory rate, airflow, and oxygen saturation. Companies like Masimo offer continuous SpO? and respiration monitoring via finger or forehead sensors. Emerging devices like ADAMM-RSM and Spire Health Tag are designed for asthma and COPD patients, helping detect early signs of exacerbation and reduce emergency visits.
Virtual and Augmented Reality in Patient Education and Therapy
VR and AR technologies are being used to educate patients with chronic respiratory conditions and improve rehabilitation outcomes. Programs like Pulmonary Rehab VR provide immersive breathing exercises and lung training, helping COPD patients improve lung function.
AI in Respiratory Devices Market
Artificial intelligence is redefining how respiratory conditions are diagnosed, monitored, and treated. Companies like ResMed use AI to personalize CPAP therapy by adjusting airflow in real time based on sleep patterns.Ultromics’ EchoGo, though focused on cardiac imaging, is paving the way for AI in respiratory diagnostics linked to heart-lung conditions. AI also powers smart inhalers that track medication usage and adherence, helping reduce hospital readmissions. As regulatory frameworks evolve, more AI-enabled respiratory devices are expected to reach market, offering real-time data analytics and predictive insights.
Trade Analysis of Respiratory Devices Industry
Global trade in respiratory devices is characterized by high-volume exports from the U.S., Germany, and China, with key imports landing in Asia-Pacific and Latin America. In 2023, the top exporters of medical ventilators, CPAP, BiPAP, and oxygen concentrators were Singapore (USD 1.78 billion), the European Union (USD 1.52 billion), the United States (USD 1.44 billion), the Netherlands (USD 1.11 billion), and Australia (USD 1.11 billion). These countries led global trade in advanced respiratory care technologies. The EU, driven by Germany and Switzerland, remains a key manufacturing and export hub for high-end ICU ventilators. Emerging markets like India and Brazil have increased imports to support growing respiratory disease burdens. Tariff barriers, regulatory delays, and shipping constraints continue to affect global trade flows.
Impact of 2025 US Tariffs on Respiratory Devices Market
The 2025 U.S. tariffs on medical imports from countries like China and Germany have increased costs for components critical to respiratory device manufacturing, such as sensors, plastic tubing, and circuit boards. Companies like Philips Respironics and GE HealthCare are now facing higher operational expenses, pushing some to consider regionalizing supply chains. These tariffs may delay product launches and increase end-user prices for home ventilators and CPAP devices. Smaller players with offshore production are particularly vulnerable as there is expected increased cost for offshore manufacturing.
Pricing Analysis of Respiratory Devices Market
The pricing of respiratory devices varies significantly based on type, functionality, and care setting. High-end devices like ICU-grade ventilators can cost upwards of USD 25,000, while portable CPAP machines are priced between USD 500 and USD 3,000.Market leaders like Philips and ResMed often command premium prices due to brand trust and innovation. For instance, AirMini AutoSet CPAP Machine, one of the smallest portable CPAP manufactured by ResMed is priced at USD 919. In contrast, emerging market players offer cost-effective alternatives to penetrate price-sensitive regions. Bulk procurement by hospitals or government schemes can drive price discounts, whereas individual purchases, particularly for homecare, reflect higher per-unit costs.
Reimbursement Scenario of Respiratory Devices Market
Reimbursement plays a critical role in adoption, especially in developed markets like the U.S., EU, and Japan. Medicare, Medicaid, and private insurers in the U.S. provide coverage for CPAP machines, oxygen concentrators, and ventilators, but reimbursement rates vary by state and device type. In Europe, public healthcare systems generally offer broader reimbursement but often have stringent approval processes. In emerging economies, limited or no reimbursement compels patients to rely on out-of-pocket spending, limiting access to advanced respiratory technologies.
Unmet Needs and Customer Expectations Analysis
Despite advancements, gaps remain in accessibility, cost-effectiveness, and usability, especially in rural and low-resource settings. Patients and healthcare providers seek quiet, portable, and low-maintenance devices with real-time feedback. There’s growing demand for seamless connectivity to EHR systems and for non-invasive, pediatric-friendly options. Unmet needs also include integration with telehealth platforms, and better battery life for portable oxygen therapy devices.
Investment & Funding Scenario of Respiratory Devices Market
The respiratory device sector has attracted substantial investment, particularly after the COVID-19 pandemic underscored the importance of respiratory support systems. Companies have raised significant venture capital or IPO funds to expand manufacturing and R&D. For instance, in January 2025, startups like Neko Health raised over USD 260M for early detection technologies that indirectly support respiratory diagnostics. The funding will accelerate the company’s expansion across Europe and the US, while boosting R&D for innovative health diagnostics. Investment is also flowing into AI-driven monitoring devices and wearable respiratory sensors, indicating sustained interest in digital and homecare-enabled respiratory solutions.
(Source:https://www.nekohealth.com/se/en/neko-health-raises-260m-series-b)
Patent Analysis of Respiratory Devices Market
|
Patent No. |
Title |
Expiry |
Assignee |
|
US20060144398A1 (https://patents.google.com/patent/US20060144398A1/en) |
Respiratory devices |
2029-07-19 |
LUNAR DESIGN Inc., Theravent Inc |
Regulatory Framework
The regulatory landscape is governed by bodies such as the U.S. FDA, European Medicines Agency (EMA), and local authorities like PMDA (Japan). Devices must meet ISO 13485 quality standards and pass rigorous clinical validation. Recent efforts by the U.S. FDA’s TPLC Advisory Program (TAP) aim to accelerate the approval of breakthrough respiratory innovations. Additionally, EU MDR regulations now demand stricter post-market surveillance for Class II and III respiratory devices. Regulatory harmonization and digital health frameworks are further evolving to accommodate software-integrated devices.
(Source:https://www.imdrf.org/)
|
Region/Country |
Regulatory Authority |
Classification System |
Approval Pathways |
Recent Developments |
|
United States |
FDA – Center for Devices and Radiological Health (CDRH) |
Class I (low risk), II (moderate), III (high) |
510(k), De Novo, PMA (Premarket Approval) |
510(k) clearance is dominant (~90% of devices). Cybersecurity and SaMD (software as a medical device) are growing focus areas. |
|
European Union |
Notified Bodies under EU MDR (2017/745) |
Class I, IIa, IIb, III |
CE Mark via Notified Body (except Class I self-certification) |
EU MDR increased clinical evidence and post-market surveillance demands; grace periods extended due to system bottlenecks. |
|
China |
National Medical Products Administration (NMPA) |
Class I, II, III |
Notification (Class I), Registration (Class II/III) |
Requires local clinical trials unless exemptions apply. Heavily regulated but rapidly harmonizing with global standards. |
|
India |
Central Drugs Standard Control Organization (CDSCO) |
Class A (low), B (moderate), C, D (high) |
Registration through SUGAM portal |
Transitioning to risk-based regulatory regime; licensing mandatory for most devices from 2023 onward. |
|
Japan |
Pharmaceuticals and Medical Devices Agency (PMDA) |
General, Controlled, Highly Controlled |
Pre-market Certification, Approval, or Notification |
Rigorous but efficient with a review partner system; good market for innovative devices post-approval. |
R&D Analysis of Respiratory Devices Market
R&D investment in the respiratory device market is focused on non-invasive, portable, and digitally connected solutions. R&D is also exploring battery-powered oxygen concentrators and advanced mask seal technologies. Clinical validation and real-world data collection remain central to innovation pathways.
In June 2025, Inogen, Inc. launched Voxi 5, a new stationary oxygen concentrator aimed at improving access to oxygen therapy for long-term care patients in the U.S. The product expanded Inogen’s portfolio beyond portable devices, enhancing market reach through established sales channels.
In May 2025, AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate), previously approved for treating COPD in adults, received UK approval with a next-generation, near-zero Global Warming Potential (GWP) propellant, marking a major step toward sustainable respiratory care without compromising therapeutic efficacy.
In April 2025, AirLife launched the MYOTouch Muscle Stimulator, the only FDA-cleared device for muscle stimulation during Posterior Sagittal Anorectoplasty (PSARP) and laparoscopic repair of anorectal malformations (ARM) in patients from birth to adolescence, further expanding its specialized respiratory and anesthesia care portfolio across North America.
(Source:https://myairlife.com/news-articles/airlife-launches-innovative-device-for-arm-repair/)
Ecosystem Analysis of Respiratory Devices Market
Raw Material Sourcing
Raw materials play a critical role in the production of respiratory devices such as ventilators, oxygen concentrators, nebulizers, and CPAP machines. Companies like 3M and DuPont supply advanced polymers, filters, and non-woven fabrics used in masks and filters. BASF contributes high-performance plastics and resins for device casings and internal components, while Celanese offers engineered materials for tubing and connectors.
Manufacturers
Global leaders in respiratory device manufacturing include Philips, known for its DreamStation and Trilogy ventilators and ResMed, which dominates the sleep apnea market with its CPAP/BiPAP solutions. Fisher & Paykel Healthcare specializes in humidification and high-flow oxygen therapy devices, while Drägerwerk AG focuses on hospital-grade ventilators and monitoring systems. These companies invest heavily in R&D, regulatory compliance, and innovation to meet diverse patient needs across acute care, home care, and sleep therapy.
Distributors and Logistics
Efficient distribution ensures the timely and safe delivery of respiratory devices to hospitals, clinics, and home care providers. Industry giants like McKesson, Cardinal Health, and Medline manage large-scale logistics operations and supply chain management across global markets. Owens & Minor plays a significant role in distributing both finished devices and critical components.
Recent Developments & Strategies
In May 2025, Viemed Healthcare announced a definitive agreement to acquire Illinois-based Lehan’s Medical Equipment, a specialized provider in respiratory care and women’s health. The acquisition, valued at a base price of USD 26 million with an additional USD 2.2 million in contingent payments, is expected to close in Q3 2025, pending customary adjustments.
(Source:https://www.hmenews.com/article/viemed-to-buy-lehans-for-26-m)
In May 2025, ResMed announced the acquisition of VirtuOx, a prominent independent diagnostic testing facility (IDTF). VirtuOx specializes in providing diagnostic services for sleep, respiratory, and cardiac conditions, enhancing ResMed’s capabilities in remote patient monitoring and expanding its footprint in digital health diagnostics.
(Source:https://www.massdevice.com/resmed-acquires-virtual-diagnostics-company-virtuox/)
In February 2025, TGen (part of City of Hope), Ginkgo Bioworks, and an international team of scientists announced a collaboration to develop RANGER, an advanced, user-friendly metagenomic sequencing tool. Designed to rapidly identify respiratory viruses, RANGER aims to support hospitals and healthcare facilities in delivering faster, more accurate diagnostics to improve patient care and outbreak response.
(Source:https://www.tgen.org/news/tgen-collaboration-tackles-respiratory-viruses-at-point-of-care/)
Key Conferences & Events (2025)
|
Conference |
Duration |
Location |
Description |
|
International Conference on Pulmonology, Respiratory Health and Medicine (ICPRHM) |
17 August, 2025 |
Chicago, Illinois, USA |
The primary aim of ICPRHM is to offer a platform for global participants to exchange ideas and experiences in person with peers from around the world. This event also facilitates the development of research and business relationships, while enabling delegates to establish international connections for future collaboration and career advancement. |
|
International Conference on Tuberculosis ICT |
July 10-11, 2025 |
New York, United States |
The International Conference on Tuberculosis (ICT), will bring together researchers, healthcare professionals, and policymakers to discuss advancements in TB diagnosis, treatment, and prevention, fostering global collaboration and innovation to combat this persistent public health threat |
|
International Conference on Pulmonology and Respiratory Medicine |
July 14–16, 2025 |
Rome, Italy |
The International Conference on Pulmonology and Respiratory Medicine, will unite global experts to explore cutting-edge therapies and innovations. Centered on the theme “Novel Approaches in Pulmonology and Respiratory Medicine,” it will spotlight breakthroughs reshaping patient care and clinical practice. |
(Source:https://www.allconferencealert.com/event/1649571)
Case Study
Bridging the Gap in CPAP Therapy with AquaVENT FD140i
Newham University Hospital’s pediatric unit faced a critical limitation: it could only administer acute CPAP therapy to babies under 10kg, and only via nasal interfaces. This excluded older or heavier children from receiving vital respiratory support, while nasal delivery posed risks like pressure sores.
The introduction of the AquaVENT FD140i transformed care delivery by enabling full facial CPAP for infants, children, and adolescents of all sizes. This device allows seamless transitions between High Flow Oxygen Therapy (HFOT) and CPAP, improving patient management and resource utilization. Its built-in 60-minute backup battery also ensures safe transfers from the Emergency Department to the Rainbow Ward.
As a result, the hospital can now treat a broader patient population with a single, efficient device. Staff have reported better CPAP sealing with face masks, enhancing therapy effectiveness and improving comfort. AquaVENT FD140i has significantly advanced pediatric respiratory care at the facility.
(Source:https://www.eakinrespiratory.com/case-study/bridging-the-gap-in-cpap-therapy/)
Conclusion
The global respiratory device market is at a pivotal juncture, shaped by rising chronic respiratory conditions, aging populations, and the growing demand for home-based care. There is a significant shift toward smart, connected devices that enable remote monitoring and early intervention, driven by AI, IoT, and wearable tech integration. Post-pandemic resilience has also spurred regulatory agility and faster adoption cycles. Companies investing in user-friendly designs, digital health ecosystems, and value-based care models are best positioned to lead. Emerging markets, with unmet needs and rising healthcare access, offer untapped growth, making localization strategies and cost-effective innovation critical for sustained success.
List of Respiratory Devices Industry Reports
Portable Oxygen Concentrators Market Analysis 2022–2034
Respiratory Devices Industry Clients Worldwide
